Logo image
Immune-mediated myasthenia gravis in a methimazole-treated cat
Journal article   Peer reviewed

Immune-mediated myasthenia gravis in a methimazole-treated cat

E.T. Bell, C.S. Mansfield and F.E. James
Journal of Small Animal Practice, Vol.53(11), pp.661-663
2012
url
Link to Published Version *Subscription may be requiredView

Abstract

A 12-year-old female neutered ragdoll crossbred cat was presented for investigation of generalised weakness and regurgitation. The cat was being treated with transdermal methimazole for hyperthyroidism, which had been diagnosed 10 weeks previously. An acetylcholine receptor antibody titre was consistent with acquired myasthenia gravis. Withdrawal of methimazole and treatment with pyridostigmine was followed by resolution of clinical signs and reduction of the acetylcholine receptor antibody titre. Medical control of hyperthyroidism was subsequently achieved with carbimazole, administered in conjunction with pyridostigmine, and no recurrence of clinical signs was observed. Myasthenia gravis is an uncommon but clinically significant adverse effect of methimazole therapy in cats, and may be caused by immunomodulatory properties of this drug. An adverse drug reaction should be considered in cats receiving methimazole that develop myasthenia gravis, and potentially also other immune-mediated disorders.

Details

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Metrics

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types
Domestic collaboration
Citation topics
1 Clinical & Life Sciences
1.213 Thyroid Disorders
1.213.168 Thyroid Disorders
Web Of Science research areas
Veterinary Sciences
ESI research areas
Plant & Animal Science
Logo image